Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

about

Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

P2860

Q36814797-7490AE24-90B0-4BB7-AC4F-CFF499A2EE7E

P2860

Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

Item

http://www.wikidata.org/entity/Q36731851

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Palivizumab use among children ...... idelines on clinical practice.

@ast

Palivizumab use among children ...... idelines on clinical practice.

@en

type

Item

label

Palivizumab use among children ...... idelines on clinical practice.

@ast

Palivizumab use among children ...... idelines on clinical practice.

@en

prefLabel

Palivizumab use among children ...... idelines on clinical practice.

@ast

Palivizumab use among children ...... idelines on clinical practice.

@en

P1476

Palivizumab use among children ...... uidelines on clinical practice

@en

P2093

Andrew S Mackie

http://www.w3.org/2001/XMLSchema#string

Charles V Rohlicek

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Bigras

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Côté

http://www.w3.org/2001/XMLSchema#string

Marc Bellavance

http://www.w3.org/2001/XMLSchema#string

Marc H Lebel

http://www.w3.org/2001/XMLSchema#string

Marc Paquet

http://www.w3.org/2001/XMLSchema#string

P2860

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Respiratory syncytial virus infection.

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

Respiratory syncytial virus infection in children with congenital heart disease: a review.

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome.

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Substantial variability in community respiratory syncytial virus season timing.

Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control.

P304

19-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19030237

http://www.w3.org/2001/XMLSchema#string

P921

birth defect

P932

2435318

http://www.w3.org/2001/XMLSchema#string

Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

about

P2860

P2860

Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932